Clinical Trial Update: Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating venetoclax with a hypomethylating agent in older or unfit adults with FLT3-mutated acute myeloid leukemia; recruitment is ongo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Dacogen (decitabine)
• VIDAZA (AZACITIDINE)
• Venclexta (venetoclax)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING